Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

Novo Nordisk stock rose after the Danish pharma giant posted better-than-expected quarterly earnings, but cut its guidance ...

BMS pledges $40B over five years to boost U.S. R&D, tech innovation, and pharmaceutical manufacturing under CEO Christopher ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.